ChIP assays showed that the binding activity of P53 to the miR-133a-3p promoter was markedly enhanced with CB treatment in FOXO1-suppressed NPC cells (Fig. 5k). This evidence concerns the gene FOXO1 and nasopharyngeal carcinoma.